Search

Your search keyword '"Soerensen , P. S."' showing total 30 results
Start Over Author "Soerensen , P. S."
30 results on '"Soerensen , P. S."'

1. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author

Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., and Leray, E.

Published
2022
Full Text
View/download PDF

2. Demonstration of Quadrature Squeezed Surface-Plasmons in a Gold Waveguide

Author

Huck, Alexander, Smolka, Stephan, Lodahl, Peter, Soerensen, Anders S., Boltasseva, Alexandra, Janousek, Jiri, and Andersen, Ulrik L.

Subjects
Quantum Physics
Abstract

We report on the efficient generation, propagation, and re-emission of squeezed long-range surface-plasmon polaritons (SPPs) in a gold waveguide. Squeezed light is used to excite the non-classical SPPs and the re-emitted quantum state is fully quantum characterized by complete tomographic reconstruction of the density matrix. We find that the plasmon-assisted transmission of non-classical light in metallic waveguides can be described by a Hamiltonian analogue to a beam splitter. This result is explained theoretically.

Published
2009
Full Text
View/download PDF

3. Spin squeezing of atomic ensembles via nuclear-electronic spin entanglement

Author

Fernholz, T., Krauter, H., Jensen, K., Sherson, J. F., Soerensen, A. S., and Polzik, E. S.

Subjects
Quantum Physics
Abstract

Entangled many body systems have recently attracted significant attention in various contexts. Among them, spin squeezed atoms and ions have raised interest in the field of precision measurements, as they allow to overcome quantum noise of uncorrelated particles. Precise quantum state engineering is also required as a resource for quantum computation, and spin squeezing can be used to create multi-partite entangled states. Two-mode spin squeezed systems have been used for elementary quantum communication protocols. Until now spin squeezing has been always achieved via generation of entanglement between different atoms of the ensemble. In this Letter, we demonstrate for the first time ensemble spin squeezing generated by engineering the quantum state of each individual atom. More specifically, we entangle the nuclear and electronic spins of $10^{12}$ Cesium atoms at room temperature. We verify entanglement and ensemble spin squeezing by performing quantum tomography on the atomic state., Comment: 5 pages, 3 figures

Published
2008
Full Text
View/download PDF

4. Light Qubit Storage and Retrieval using Macroscopic Atomic Ensembles

Author

Sherson, J., Soerensen, A. S., Fiurasek, J., Moelmer, K., and Polzik, E.

Subjects
Quantum Physics
Abstract

We present an experimentally feasible protocol for the complete storage and retrieval of arbitrary light states in an atomic quantum memory using the well-established Faraday interaction between light and matter. Our protocol relies on multiple passages of a single light pulse through the atomic ensemble without the impractical requirement of kilometer long delay lines between the passages. Furthermore, we introduce a time dependent interaction strength which enables storage and retrieval of states with arbitrary pulse shapes. The fidelity approaches unity exponentially without squeezed or entangled initial states, as illustrated by explicit calculations for a photonic qubit., Comment: 4 pages, 3 figures For his new version, the original paper has substantially rewritten to make it clearer including completely new introduction and conclusions and a rearrangement of the middle part. A minor mistake in the numerical results has been found and corrected, which resulted in higher values for the fidelities

Published
2005
Full Text
View/download PDF

6. Impact of methodological choices in comparative effectiveness studies:application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author

Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., Leray, E., Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., and Leray, E.

Abstract

Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Methods: Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Results: Overall, 5,148 relapsing–remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. Conclusions: This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is

Published
2022

7. Reporting clinical trials: full access to all the data

Author

Rosenberg, R N, Aminoff, M, Boller, F, Soerensen, P S, Griggs, R C, Hachinski, V, Hallett, M, Johnson, R T, Kennard, C, Lang, A E, Lees, A J, Lisak, R, Newsom-Davis, J, Pedley, T A, SeIzer, M E, and Zochodne, D

Published
2002

8. Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management

Author

Fernández, O., primary, Delvecchio, M., additional, Edan, G., additional, Fredrikson, S., additional, Giovannoni, G., additional, Hartung, H.-P., additional, Havrdova, E., additional, Kappos, L., additional, Pozzilli, C., additional, Soerensen, P. S., additional, Tackenberg, B., additional, Vermersch, P., additional, and Comi, G., additional

Published
2018
Full Text
View/download PDF

9. Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2:Progressive MS, paediatric MS, pregnancy and general management

Author

Fernández, O., Delvecchio, M., Edan, G., Fredrikson, S., Giovannoni, G., Hartung, H. P., Havrdova, E., Kappos, L., Pozzilli, C., Soerensen, P. S., Tackenberg, B., Vermersch, P., Comi, G., Fernández, O., Delvecchio, M., Edan, G., Fredrikson, S., Giovannoni, G., Hartung, H. P., Havrdova, E., Kappos, L., Pozzilli, C., Soerensen, P. S., Tackenberg, B., Vermersch, P., and Comi, G.

Abstract

Background and purpose: The European Charcot Foundation supported the development of a set of surveys to understand current practice patterns for the diagnosis and management of multiple sclerosis (MS) in Europe. Part 2 of the report summarizes survey results related to secondary progressive MS (SPMS), primary progressive MS (PPMS), pregnancy, paediatric MS and overall patient management. Methods: A steering committee of MS neurologists developed case- and practice-based questions for two sequential surveys distributed to MS neurologists throughout Europe. Results: Respondents generally favoured changing rather than stopping disease-modifying treatment (DMT) in patients transitioning from relapsing−remitting MS to SPMS, particularly with active disease. Respondents would not initiate DMT in patients with typical PPMS symptoms, although the presence of ≥1 spinal cord or brain gadolinium-enhancing lesion might affect that decision. For patients considering pregnancy, respondents were equally divided on whether to stop treatment before or after conception. Respondents strongly favoured starting DMT in paediatric MS with active disease; recommended treatments included interferon, glatiramer acetate and, in John Cunningham virus negative patients, natalizumab. Additional results regarding practice-based questions and management are summarized. Conclusions: Results of part 2 of the survey of diagnostic and treatment practices for MS in Europe largely mirror results for part 1, with neurologists in general agreement about the treatment and management of SPMS, PPMS, pregnancy and paediatric MS as well as the general management of MS. However, there are also many areas of disagreement, indicating the need for evidence-based recommendations and/or guidelines.

Published
2018

10. Survey of diagnostic and treatment practices for multiple sclerosis in Europe

Author

Fernández, O, Delvecchio, M, Edan, G, Fredrikson, S, Gionvannoni, G, Hartung, H-P, Havrdova, E, Kappos, L, Pozzilli, C, Soerensen, P S, Tackenberg, B, Vermersch, P, Comi, G, Fernández, O, Delvecchio, M, Edan, G, Fredrikson, S, Gionvannoni, G, Hartung, H-P, Havrdova, E, Kappos, L, Pozzilli, C, Soerensen, P S, Tackenberg, B, Vermersch, P, and Comi, G

Abstract

BACKGROUND AND PURPOSE: Up-to-date information is needed on the extent to which neurologists treating multiple sclerosis (MS) in Europe are integrating rapidly evolving diagnostic criteria, disease-modifying therapies and recommendations for monitoring disease activity into their clinical practice.METHODS: A steering committee of MS neurologists used a modified Delphi process to develop case- and practice-based questions for two sequential surveys distributed to MS neurologists throughout Europe. Case-based questions were developed for radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and RRMS with breakthrough disease.RESULTS: Multiple sclerosis neurologists from 11 European countries responded to survey 1 (n = 233) and survey 2 (n = 171). Respondents agreed that they would not treat the patients in the RIS or CIS cases but would treat a patient with a relatively mild form of RRMS. Choice of treatment was evenly distributed among first-line injectables and oral treatments for mild RRMS, and moved to second-line treatment as the RRMS case increased in severity. Additional results on RRMS with breakthrough disease are presented.CONCLUSIONS: Although there was general agreement on some aspects of treatment, responses to other management and clinical practice questions varied considerably. These results, which reflect current clinical practice patterns, highlight the need for additional MS treatment education and awareness and may help inform the development of MS practice guidelines in Europe.

Published
2017

17. Reporting clinical trials: Full access to all the data

Author

Rosenberg, R. N., Aminoff, M., Boller, F., Soerensen, P. S., Robert Griggs, Hachinski, V., Hallet, M., Johnson, R. T., Kennard, C., Lang, A. E., Lisak, R., Newsom, J., Pedley, T. A., Selzer, M. E., and Zochodne, D.

20. ChemInform Abstract: Synthesis and Synthetic Utility of 3‐Isoxazolols

Author

Soerensen, Ulrik S. and Krogsgaard‐Larsen, Povl

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Published
2002
Full Text
View/download PDF

21. ChemInform Abstract: Structural Determinants for AMPA Agonist Activity of Aryl or Heteroaryl Substituted AMPA Analogues. Synthesis and Pharmacology.

Author

Soerensen, Ulrick S., Falch, Erik, Stensboel, Tine B., Jaroszewski, Jerzy W., Madsen, Ulf, and Krogsgaard‐Larsen, Povl

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Published
2001
Full Text
View/download PDF

22. ChemInform Abstract: A Novel Route to 5‐Substituted 3‐Isoxazolols. Cyclization of N,O‐DiBoc β‐Keto Hydroxamic Acids Synthesized via Acyl Meldrum′s Acids.

Author

Soerensen, Ulrik S., Falch, Erik, and Krogsgaard‐Larsen, Povl

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Published
2000
Full Text
View/download PDF

26. ChemInform Abstract: Synthesis of Novel 3′‐C‐Branched 2′‐Deoxynucleosides. Incorporation of 3′‐C‐(3‐Hydroxypropyl)thymidine into Oligodeoxynucleotides.

Author

PFUNDHELLER, H. M., JOERGENSEN, P. N., SOERENSEN, U. S., SHARMA, S. K., GRIMSTRUP, M., STROECH, C., NIELSEN, P., VISWANADHAM, G., OLSEN, C. E., and WENGEL, J.

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Published
1998
Full Text
View/download PDF

28. Survey of diagnostic and treatment practices for multiple sclerosis in Europe

Author

G. Comi, Patrick Vermersch, Carlo Pozzilli, B. Tackenberg, P. S. Soerensen, Gilles Edan, H.-P. Hartung, M. Delvecchio, Ludwig Kappos, Oscar Fernández, G. Gionvannoni, Sten Fredrikson, Eva Havrdova, SDA Bocconi Scuola di Direzione Aziendale, Service de Neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Vision, Action et Gestion d'informations en Santé (VisAGeS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes 1 (UR1), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Department of Clinical Neurosciences, Neurology Division, Karolinska Institutet, Queen Mary's School of Medicine and Dentistry, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Department of Neurological Sciences, University of Roma 'La Sapienza', Danish Multiple Sclerosis Research Centre, Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Department of Neurology, Philipps Universität Marburg, Hospital Regional Universitario Carlos Haya, Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), departmet of Neurology, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Department of neurology, Charles University [Prague] (CU), Department of Neurology [Suisse], University Hospital Basel [Basel], Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Philipps Universität Marburg = Philipps University of Marburg, CHU Lille, Inflammation: mécanismes et régulation et interactions avec la nutrition et les candidoses, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, European Charcot Foundation, Barillot, Christian, Fernã¡ndez, O., Delvecchio, M., Edan, G., Fredrikson, S., Gionvannoni, G., Hartung, H. . P., Havrdova, E., Kappos, L., Pozzilli, C., Soerensen, P. S., Tackenberg, B., Vermersch, P., Comi, Giancarlo, Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Université de Lille, Université de Lille, Droit et Santé-Institut National de la Santé et de la Recherche Médicale (INSERM), IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-CentraleSupélec-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), and Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)

Subjects
Male, MESH: Multiple Sclerosis, Relapsing-Remitting, Delphi Technique, Modified delphi, Disease, MESH: Health Care Surveys, Relapsing-Remitting, Spinal Puncture, MESH: Delphi Technique, MESH: Magnetic Resonance Imaging, 0302 clinical medicine, Surveys and Questionnaires, relapsingâ remitting, 030212 general & internal medicine, clinically isolated syndrome, radiologically isolated syndrome, relapsing−remitting, Adult, Disease Progression, Europe, Female, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Neurologists, Health Care Surveys, Neurology, Neurology (clinical), Clinically isolated syndrome, 3. Good health, Clinical Practice, MESH: Disease Progression, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], medicine.medical_specialty, Steering committee, MESH: Spinal Puncture, relapsing−remitting, Disease activity, 03 medical and health sciences, medicine, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Mild form, MESH: Neurologists, MESH: Surveys and Questionnaires, MESH: Humans, business.industry, Multiple sclerosis, MESH: Adult, MESH: Multiple Sclerosis, medicine.disease, MESH: Male, Family medicine, Physical therapy, MESH: Europe, business, MESH: Female, 030217 neurology & neurosurgery
Abstract

International audience; Background and purpose - Up-to-date information is needed on the extent to which neurologists treating multiple sclerosis (MS) in Europe are integrating rapidly evolving diagnostic criteria, disease-modifying therapies and recommendations for monitoring disease activity into their clinical practice. Methods - A steering committee of MS neurologists used a modified Delphi process to develop case- and practice-based questions for two sequential surveys distributed to MS neurologists throughout Europe. Case-based questions were developed for radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and RRMS with breakthrough disease. Results - Multiple sclerosis neurologists from 11 European countries responded to survey 1 (n = 233) and survey 2 (n = 171). Respondents agreed that they would not treat the patients in the RIS or CIS cases but would treat a patient with a relatively mild form of RRMS. Choice of treatment was evenly distributed among first-line injectables and oral treatments for mild RRMS, and moved to second-line treatment as the RRMS case increased in severity. Additional results on RRMS with breakthrough disease are presented. Conclusions - Although there was general agreement on some aspects of treatment, responses to other management and clinical practice questions varied considerably. These results, which reflect current clinical practice patterns, highlight the need for additional MS treatment education and awareness and may help inform the development of MS practice guidelines in Europe.

Published
2017
Full Text
View/download PDF

29. Reporting clinical trials: full access to all the data.

Author

Rosenberg RN, Aminoff M, Boller F, Soerensen PS, Griggs RC, Hallett M, Johnson RT, Kennard C, Lang AE, Lees AJ, Lisak R, Newsom-Davis J, Pedley TA, Selzer ME, and Zochodne D

Subjects
Disclosure, Humans, Peer Review, Research, Clinical Trials as Topic standards
Published
2001

30. Characteristics of patients with short and long survivals after detection of intracranial metastases from breast cancer.

Author

Kamby C and Soerensen PS

Subjects
Adult, Brain Neoplasms mortality, Breast Neoplasms therapy, Combined Modality Therapy, Demography, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Brain Neoplasms secondary, Breast Neoplasms pathology
Abstract

The clinical course of 106 patients with brain metastases from breast cancer was retrospectively studied. Median time of survival after detection of intracranial metastases (SAR(ICM] was 14 weeks (95% confidence limits: 10-19 weeks), and 25% of the patients survived for more than 37 weeks, while only 17% survived for one year. The occurrence of clinical, pathoanatomical and therapeutical variables in these patients were analyzed in a subgroup of 57 patients, who survived for less than 16 weeks, and compared with a subgroup of 49 patients, who survived for more than 16 weeks after detection brain metastases. None of the variables studied were associated with either of the two prognostic groups. Patients with short SAR(ICM) had, however, a greater number of extra-cranial metastases at recurrence in the brain compared to patients with SAR(ICM) more than 16 weeks (p = 0.07). Patients with SAR(ICM) less than 16 weeks had a somewhat shorter recurrence-free interval (p = 0.22) and a significantly shorter time from primary diagnosis until detection of brain metastases (p = 0.04). Probably as a consequence of this, these patients had a shorter survival from primary diagnosis as well as from first recurrence. The findings may indicate that the differences in survival of patients with brain metastases are mainly due to differences in the rate of disease progression.

Published
1988
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results